Market Updates
Illumina Lowered Annual Revenue Growth Estimate and Forecasted Loss
Scott Peters
12 Aug, 2022
New York City
Illumina, Inc plunged 8.8% to $207.67 after the gene-sequencing technology company said second quarter revenues increased 3% to $1.26 billion from $1.13 billion a year ago.
The company swung to a net loss of $535 million from $185 million a year ago.
The current quarter included $609 million in legal contingencies for the potential fine that the European Commission may impose of up to 10% of our consolidated annual revenues and an estimated accrual of $156 million related to the settlement of litigation with the U.K.-based BGI Group in July 2022.
In the quarter, the diluted loss per share was $3.40 compared to a profit of $1.26 a year ago.
The company also lowered its 2022 revenue growth outlook to between 4% and 5% and GAAP diluted loss per share between $2.93 and $2.78.
The company earlier guided in May at the time of the release of the first quarter results consolidated revenue growth in the range of 14% to 16% and GAAP earnings per diluted share of $2.33 to $2.53.
Annual Returns
| Company | Ticker | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|
Earnings
| Company | Ticker | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|